Design Novel Dual Agonists for Treating Type-2 Diabetes by Targeting Peroxisome Proliferator-Activated Receptors with Core Hopping Approach

@article{Ma2012DesignND,
  title={Design Novel Dual Agonists for Treating Type-2 Diabetes by Targeting Peroxisome Proliferator-Activated Receptors with Core Hopping Approach},
  author={Y. Ma and Shu-Qing Wang and Wei-Ren Xu and Run-Ling Wang and K. Chou},
  journal={PLoS ONE},
  year={2012},
  volume={7}
}
Owing to their unique functions in regulating glucose, lipid and cholesterol metabolism, PPARs (peroxisome proliferator-activated receptors) have drawn special attention for developing drugs to treat type-2 diabetes. By combining the lipid benefit of PPAR-alpha agonists (such as fibrates) with the glycemic advantages of the PPAR-gamma agonists (such as thiazolidinediones), the dual PPAR agonists approach can both improve the metabolic effects and minimize the side effects caused by either agent… Expand
Find novel dual-agonist drugs for treating type 2 diabetes by means of cheminformatics
TLDR
Ten novel compounds found by targeting peroxisome proliferator-activated receptors (PPARs) using virtual screening and core hopping approaches are reported, finding that these novel dual agonists not only possessed the same function as ragaglitazar did in activating PPARα and PPARγ, but they also had more favorable conformation for binding to the two receptors. Expand
Identification of dual PPARα/γ agonists and their effects on lipid metabolism.
TLDR
Virtual screening of natural product libraries, using both structure-based and ligand-based drug discovery approaches, identified ten potential dual PPARα/γ agonist lead compounds and in vitro assays confirmed these compounds to show no statistically significant toxicity to cells. Expand
SAR and Computer-Aided Drug Design Approaches in the Discovery of Peroxisome Proliferator-Activated Receptor γ Activators: A Perspective
Activators of PPARγ, Troglitazone (TGZ), Rosiglitazone (RGZ), and Pioglitazone (PGZ) were introduced for treatment of Type 2 diabetes, but TGZ and RGZ have been withdrawn from the market along withExpand
Identification of novel multitargeted PPARα/γ/δ pan agonists by core hopping of rosiglitazone
TLDR
Molecular dynamics simulation of the representative Cpd#1 showed more favorable binding conformation for PPARs receptor than the original ligand, which could act as a PPARα/γ/δ pan agonist for novel antidiabetic drug research. Expand
Peroxisome proliferator‐activated receptor α ligands and modulators from dietary compounds: Types, screening methods and functions
TLDR
Recent advances in knowledge of PPARα are discussed, including its structure, function, and ligand and modulator screening assays, and the different types of dietary PPAR α ligands and modulators are summarized. Expand
To Probe Full and Partial Activation of Human Peroxisome Proliferator-Activated Receptors by Pan-Agonist Chiglitazar Using Molecular Dynamics Simulations
TLDR
Detailed dynamics analyses support that the conformation and dynamics of helix 12 play a critical role in determining the activities of the different types of ligands and may aid in further development of this new generation of medication. Expand
SCREENING AND MOLECULAR DOCKING STUDIES OF NEW NATURAL AGONISTS AGAINST PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA TARGETED TO TREAT OBESITY
TLDR
The docking methodology suggested that two molecules zinc02091671 and zinc02137525 were found to reproduce the similar type of interactions such as that of the known inhibitor and crystal ligand, and can be advanced the in vitro based evaluation. Expand
Critical Insight into the Design of PPAR-γ Agonists by Virtual Screening Techniques.
TLDR
It is concluded that to achieve a convincing and reliable design of PPAR-γ agonist by virtual screening techniques, customized workflow comprising of appropriate models is essential in which methods may be applied either sequentially or simultaneously. Expand
Design, synthesis, and evaluation of novel l-phenylglycine derivatives as potential PPARγ lead compounds.
TLDR
The in vitro screening of peroxisome proliferator-activated receptor gamma (PPARγ) activated activity, α-glucosidase inhibitory and dipeptidyl peptidase-4 inhibitory activities showed that the novel molecule M5 was selected as the hit compound from which the TM3 and TM4 series of compounds were further designed and synthesized. Expand
In vitro evaluation of dual agonists for PPARγ/β from the flower of Edgeworthia gardneri (wall.) Meisn.
TLDR
The results demonstrated that n-hexane, ethyl acetate and n-butanol extracts from the flower of E.gardneri were the new agonists for PPARγ and PPARβ. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 84 REFERENCES
Safety issues and prospects for future generations of PPAR modulators.
TLDR
This review mainly focuses on the preclinical and clinical adverse events of PPAR agonists that could be of concern when considering the development of new PPar agonists. Expand
PPAR dual agonists: are they opening Pandora's Box?
TLDR
The present review critically analyzes the protective and detrimental effect of PPAR agonists in diabetic cardiovascular complications and discusses the newly developed PPARalpha/delta and PPAR gamma/ delta dual agonists and PParalpha/gamma/d delta pan agonists which may open a new vista in the management of diabetic cardiovascular complication in near future. Expand
Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes.
TLDR
The combination of increased insulin sensitivity, improved lipid profile, and reduced inflammation may explain the cardiovascular benefits of this class of drugs. Expand
Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors
  • H. Xu, M. Lambert, +9 authors T. Willson
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 2001
TLDR
Through comparison of the crystal structures of the ligand binding domains of the three human PPARs, molecular determinants of subtype selectivity are identified and will aid the design of drugs for the treatments of metabolic and cardiovascular diseases. Expand
Docking and molecular dynamics simulations of peroxisome proliferator activated receptors interacting with pan agonist sodelglitazar.
TLDR
It was revealed by the MD simulations that the structures of the receptors remained quite stable during the simulations and that the important AF-2 helix showed less flexibility after binding with sodelglitazar. Expand
Structure of the PPARα and -γ Ligand Binding Domain in Complex with AZ 242; Ligand Selectivity and Agonist Activation in the PPAR Family
Abstract Background: The peroxisome proliferator-activated receptors (PPAR) are ligand-activated transcription factors belonging to the nuclear receptor family. The roles of PPARα in fatty acidExpand
The peroxisome proliferator-activated receptor:retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs.
TLDR
It is demonstrated that a metabolically stabilized fatty acid is a potent PPAR activator, suggesting that fatty acids, or their acyl CoA derivatives, may be the natural ligands of PPAR. Expand
Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family.
TLDR
A general model for ligand activation in the PPAR family is suggested and a comparison of the ligand binding sites reveals a molecular explanation for subtype selectivity and provides a basis for rational drug design. Expand
Virtual Screening as a Technique for PPAR Modulator Discovery
TLDR
This review summarizes the high potential for obtaining further fundamental understanding of PPARγ biology and development of novel therapies for treating chronic inflammatory diseases through evolution and implementation of computational screening processes for immunotherapeutics in conjunction with experimental methods for calibration and validation of results. Expand
Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar.
TLDR
A new and improved synthesis of the peroxisome proliferator-activated receptor (PPAR) agonist ragaglitazar applicable for large-scale preparation has been developed based on a novel enzymatic kinetic resolution step. Expand
...
1
2
3
4
5
...